secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019674
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q1 revenue $23.5M vs $9.0M YoY; cash $204.5M; pipeline advances
----------------------------------------------------------------------

- Revenue $23.5M in Q1 2023, up from $9.0M Q1 2022, driven by BMS project progress, Astellas milestone, and AbbVie termination revenue recognition.
- Cash, equivalents and investments $204.5M at Mar 31, 2023, versus $193.7M at Dec 31, 2022; includes $35M Moderna upfront and $5M Astellas milestone.
- AbbVie terminated CD71 collaboration; CX-2029 not advanced to additional studies; CytomX evaluating full rights acquisition and next-gen CD71 strategies.
- BMS advanced BMS-986288 (anti-CTLA-4 Probody) from Phase 1 to Phase 2 as lead next-gen CTLA-4 program.
- Marcia Belvin promoted to Chief Scientific Officer; IND filings for CX-2051 and CX-801 targeted for H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/0000950170-23-019674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/ctmx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer